JP2023524573A - Ｓａｒｓ－ｃｏｖ－２スパイクタンパク質に結合する単一ドメイン抗体 - Google Patents

Ｓａｒｓ－ｃｏｖ－２スパイクタンパク質に結合する単一ドメイン抗体 Download PDF

Info

Publication number
JP2023524573A
JP2023524573A JP2022567557A JP2022567557A JP2023524573A JP 2023524573 A JP2023524573 A JP 2023524573A JP 2022567557 A JP2022567557 A JP 2022567557A JP 2022567557 A JP2022567557 A JP 2022567557A JP 2023524573 A JP2023524573 A JP 2023524573A
Authority
JP
Japan
Prior art keywords
seq
cdr3
cdr2
rbd
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022567557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524573A5 (https=
Inventor
フオ，ジアーンドーン
オーウェンス，レイモンド
ナイスミス，ジェームズ
スチュアート，デビッド
Original Assignee
ザ・ロザリンド・フランクリン・インスティテュート
ダイアモンド ライト ソース リミテッド
オックスフォード ユニヴァーシティ イノヴェーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006589.2A external-priority patent/GB202006589D0/en
Priority claimed from GBGB2010861.9A external-priority patent/GB202010861D0/en
Application filed by ザ・ロザリンド・フランクリン・インスティテュート, ダイアモンド ライト ソース リミテッド, オックスフォード ユニヴァーシティ イノヴェーション リミテッド filed Critical ザ・ロザリンド・フランクリン・インスティテュート
Publication of JP2023524573A publication Critical patent/JP2023524573A/ja
Publication of JP2023524573A5 publication Critical patent/JP2023524573A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022567557A 2020-05-04 2021-05-04 Ｓａｒｓ－ｃｏｖ－２スパイクタンパク質に結合する単一ドメイン抗体 Withdrawn JP2023524573A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2006589.2A GB202006589D0 (en) 2020-05-04 2020-05-04 Single domain antibodies
GB2006589.2 2020-05-04
GBGB2010861.9A GB202010861D0 (en) 2020-07-14 2020-07-14 Single domain antibodies
GB2010861.9 2020-07-14
PCT/GB2021/051069 WO2021224606A1 (en) 2020-05-04 2021-05-04 Single domain antibodies binding to sars-cov-2 spike protein

Publications (2)

Publication Number Publication Date
JP2023524573A true JP2023524573A (ja) 2023-06-12
JP2023524573A5 JP2023524573A5 (https=) 2024-05-02

Family

ID=75977769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567557A Withdrawn JP2023524573A (ja) 2020-05-04 2021-05-04 Ｓａｒｓ－ｃｏｖ－２スパイクタンパク質に結合する単一ドメイン抗体

Country Status (7)

Country Link
US (1) US20230348572A1 (https=)
EP (1) EP4146689A1 (https=)
JP (1) JP2023524573A (https=)
KR (1) KR20230150184A (https=)
AU (1) AU2021269176A1 (https=)
CA (1) CA3177766A1 (https=)
WO (1) WO2021224606A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104933A1 (en) * 2021-12-07 2023-06-15 new/era/mabs GmbH Camelid antibodies for use in therapy and diagnosis
EP4194054A1 (en) * 2021-12-07 2023-06-14 new/era/mabs GmbH Camelid antibodies for use in therapy and diagnosis
CN114478757B (zh) * 2022-03-31 2022-07-05 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
CN114736293B (zh) * 2022-06-14 2022-09-02 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用
WO2025147701A1 (en) * 2024-01-07 2025-07-10 Abalone Bio, Inc. Cannabinoid receptor type 2 antibodies and uses thereof
WO2026006639A1 (en) * 2024-06-26 2026-01-02 Rutgers, The State University Of New Jersey Antigen binding molecules targeting transferrin receptor 1
GB202413879D0 (en) 2024-09-20 2024-11-06 Rosalind Franklin Inst Single domain antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333722A (zh) 2020-03-03 2020-06-26 江苏省疾病预防控制中心(江苏省公共卫生研究院) SARS-CoV-2抑制剂及其应用
CN114163523B (zh) 2020-03-17 2023-07-18 北京凯因科技股份有限公司 一种针对新型冠状病毒的单域抗体及其应用
CN111647076B (zh) 2020-04-27 2021-02-26 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用

Also Published As

Publication number Publication date
AU2021269176A8 (en) 2022-12-08
KR20230150184A (ko) 2023-10-30
AU2021269176A1 (en) 2022-11-24
US20230348572A1 (en) 2023-11-02
CA3177766A1 (en) 2021-11-11
WO2021224606A1 (en) 2021-11-11
EP4146689A1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
Huo et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Dang et al. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
Sauer et al. Structural basis for broad coronavirus neutralization
Huo et al. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Dejnirattisai et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain
JP2023524573A (ja) Ｓａｒｓ－ｃｏｖ－２スパイクタンパク質に結合する単一ドメイン抗体
Nutalai et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Bianchini et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Rossey et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
CN112390879B (zh) 靶向SARS-CoV-2的抗体及其制备方法和应用
US20240043507A1 (en) Antibodies
EP2938632A1 (en) Anti-granulysin antibodies and methods of use thereof
Chen et al. Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains
US12030927B2 (en) Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
US20250154231A1 (en) Antibodies capable of binding to the spike protein of cononavirus sars-cov-2
Gorman et al. Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
EP3992205A1 (en) Sars coronavirus-2 spike protein binding compounds
Abu-Shmais et al. A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein
Huo et al. Structural characterisation of a nanobody derived from a naïve library that neutralises SARS-CoV-2
Walter et al. Highly potent bispecific sybodies neutralize SARS-CoV-2
Addetia et al. Potent neutralization of Marburg virus by a vaccine-elicited antibody
WO2023148641A1 (en) Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof
CN116867801A (zh) 与SARS-CoV-2刺突蛋白结合的单域抗体
Zhou et al. Neutralizing antibodies elicited by Nipah virus G-head nanoparticle target diverse sites and inhibit receptor binding and fusion
Zhou et al. Antigenic landscape of Nipah virus attachment glycoprotein analysis reveals a protective immunodominant epitope across species

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20221104

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20230203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240418

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417